Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.

Autor: Memoli M; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; Department of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, Italy., Paviglianiti A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Malard F; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France., Battipaglia G; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France., Brissot E; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France., Médiavilla C; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France., Bianchessi A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Banet A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Van de Wyngaert Z; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Ledraa T; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Belhocine R; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Sestili S; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Lapusan S; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Hirsch P; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.; AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France., Favale F; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.; AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France., Boussaroque A; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.; AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France., Bonnin A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Vekhoff A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France., Legrand O; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France., Mohty M; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France., Duléry R; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2021 Feb; Vol. 62 (2), pp. 419-427. Date of Electronic Publication: 2020 Oct 05.
DOI: 10.1080/10428194.2020.1827246
Abstrakt: We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related ( n  = 5), matched unrelated ( n  = 16), mismatched unrelated ( n  = 1), and haploidentical ( n  = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje